After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved

The devastations of the public markets and the repeated rejections handed down by the FDA have added up to a dim future for Zosano Pharma as it appears the 16-year-old biotech’s journey is coming to an end.